Ertapenem: interakcje
Ertapenem (Invanz), antybiotyk: 75 udokumentowanych interakcji w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 48, umiarkowane: 27, niewielkie: 0, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (48)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (etykieta leku Ertapenem, Przeciwwskazania)
- ProbenecydPoważna
Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (etykieta leku Ertapenem, Interakcje z innymi lekami)
- Probenecyd + kolchicynaPoważna
Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (etykieta leku Ertapenem, Interakcje z innymi lekami)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (etykieta leku Ertapenem, Przeciwwskazania)
Umiarkowane interakcje (27)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)
Sprawdź, jak Ertapenem łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.